loading
前日終値:
$168.52
開ける:
$168.87
24時間の取引高:
550.73K
Relative Volume:
0.46
時価総額:
$17.01B
収益:
$3.10B
当期純損益:
$668.60M
株価収益率:
26.00
EPS:
6.5044
ネットキャッシュフロー:
$831.30M
1週間 パフォーマンス:
+4.82%
1か月 パフォーマンス:
+7.01%
6か月 パフォーマンス:
+17.94%
1年 パフォーマンス:
+35.07%
1日の値動き範囲:
Value
$168.49
$171.43
1週間の範囲:
Value
$160.42
$171.43
52週間の値動き範囲:
Value
$122.14
$171.43

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1098)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
2,000
Name
Twitter
Name
次回の収益日
2026-07-29
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NBIX icon
NBIX
Neurocrine Biosciences Inc
169.14 16.94B 3.10B 668.60M 831.30M 6.5044
TAK icon
TAK
Takeda Pharmaceutical Co Adr
15.88 50.27B 29.91B 1.30B 3.49B 0.4056
HLN icon
HLN
Haleon Plc Adr
9.315 40.72B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
33.28 38.67B 17.53B 1.58B 444.18M 1.3457
ZTS icon
ZTS
Zoetis Inc
73.98 31.90B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
546.26 23.03B 3.17B 1.29B 1.01B 27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 開始されました Wolfe Research Outperform
2026-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
04:00 AM

Bull of the Day: Neurocrine Biosciences (NBIX) - Zacks Investment Research

04:00 AM
pulisher
Jun 28, 2026

Neurocrine Biosciences, Inc.(NasdaqGS: NBIX) dropped from Russell 1000 Dynamic Index - marketscreener.com

Jun 28, 2026
pulisher
Jun 28, 2026

Neurocrine Biosciences (NBIX) Is Up 6.5% After CRENESSITY Shows Broad CAH Benefits at ENDO 2026 – Has The Bull Case Changed? - Yahoo Finance

Jun 28, 2026
pulisher
Jun 28, 2026

Neurocrine Biosciences (NBIX) Unveils New CRENESSITY Data For Classic CAH And Rare Subtype - Yahoo Finance

Jun 28, 2026
pulisher
Jun 28, 2026

Neurocrine Biosciences (NBIX) Showed New CRENESSITY Data, Is The Stock Still Cheap? - simplywall.st

Jun 28, 2026
pulisher
Jun 28, 2026

Neurocrine Biosciences (NBIX): High Growth NASDAQ Stocks to Buy Now - Insider Monkey

Jun 28, 2026
pulisher
Jun 27, 2026

Neurocrine Biosciences (NBIX): High Growth Stocks to Buy Right Now - Insider Monkey

Jun 27, 2026
pulisher
Jun 26, 2026

Neurocrine Biosciences, Inc. Actuals & Estimates (NASDAQ:NBIX) - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Form 144 NEUROCRINE BIOSCIENCES INC For: 26 June - Investing.com UK

Jun 26, 2026
pulisher
Jun 26, 2026

Form 144 NEUROCRINE BIOSCIENCES INC For: 26 June By Investing.com - Investing.com Australia

Jun 26, 2026
pulisher
Jun 26, 2026

Price to earnings forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Neurocrine Biosciences Inc (NBIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

Price to sales forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

Costco Stock And 2 Low Risk Picks Built For Volatile Markets - simplywall.st

Jun 25, 2026
pulisher
Jun 25, 2026

Neurocrine Biosciences, Inc. Actuals & Estimates (DUS:NB3) - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

NBIX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

NB3 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

5 High Growth Stocks to Buy Right Now - Insider Monkey

Jun 25, 2026
pulisher
Jun 25, 2026

Neurocrine Biosciences Inc (NBIX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 25, 2026
pulisher
Jun 24, 2026

Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance

Jun 24, 2026
pulisher
Jun 24, 2026

Best Momentum Stocks to Buy for June 24th - Yahoo Finance Singapore

Jun 24, 2026
pulisher
Jun 24, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Fits the Profile of a Classic GARP Stock Under the Peter Lynch Framework - ChartMill

Jun 24, 2026
pulisher
Jun 24, 2026

Neurocrine Biosciences Inc (NBIX) Institutional Confidence - TradingKey

Jun 24, 2026
pulisher
Jun 24, 2026

Neurocrine Biosciences Inc (NBIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 24, 2026
pulisher
Jun 24, 2026

New Strong Buy Stocks for June 24th - Yahoo Finance Singapore

Jun 24, 2026
pulisher
Jun 24, 2026

Best Value Stocks to Buy for June 24th - Yahoo Finance Singapore

Jun 24, 2026
pulisher
Jun 24, 2026

Neurocrine Biosciences (NBIX) Pe Ratio (TTM) - Zacks Investment Research

Jun 24, 2026
pulisher
Jun 23, 2026

What Neurocrine Biosciences (NBIX)'s New CRENESSITY CAH Data Means For Shareholders - Sahm

Jun 23, 2026
pulisher
Jun 22, 2026

Stifel reiterates Neurocrine Bio stock rating on Vykat potential By Investing.com - Investing.com Nigeria

Jun 22, 2026
pulisher
Jun 22, 2026

Stifel reiterates Neurocrine Bio stock rating on Vykat potential - Investing.com

Jun 22, 2026
pulisher
Jun 22, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A 22.8% Potential Upside Amid Strong Growth Prospects - DirectorsTalk Interviews

Jun 22, 2026
pulisher
Jun 21, 2026

Neurocrine Biosciences Inc (NBIX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 21, 2026
pulisher
Jun 20, 2026

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Decent Value Play with Strong Fundamentals - ChartMill

Jun 20, 2026
pulisher
Jun 19, 2026

Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data - simplywall.st

Jun 19, 2026
pulisher
Jun 18, 2026

Neurocrine Biosciences Inc (NBIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

NBIX News | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill

Jun 18, 2026
pulisher
Jun 17, 2026

Neurocrine Biosciences Inc (NBIX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Neurocrine Biosciences Inc (NBIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Neurocrine Biosciences Inc (NBIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026
pulisher
Jun 16, 2026

Citi Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $246 - Moomoo

Jun 16, 2026
pulisher
Jun 16, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High-Growth Momentum Breakout Candidate - ChartMill

Jun 16, 2026
pulisher
Jun 15, 2026

Neurocrine presents long-term data on Prader-Willi drug By Investing.com - Investing.com South Africa

Jun 15, 2026
pulisher
Jun 15, 2026

Neurocrine presents long-term data on Prader-Willi drug - Investing.com

Jun 15, 2026
pulisher
Jun 15, 2026

Neurocrine presents case study on Crenessity for rare CAH subtype By Investing.com - Investing.com Australia

Jun 15, 2026
pulisher
Jun 15, 2026

Neurocrine presents case study on Crenessity for rare CAH subtype - Investing.com

Jun 15, 2026
pulisher
Jun 15, 2026

Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period - PR Newswire

Jun 15, 2026
pulisher
Jun 15, 2026

Neurocrine Biosciences (NBIX) Presents First Retrospective Case Series of CRENESSITY - StreetInsider

Jun 15, 2026
pulisher
Jun 15, 2026

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026 - The Grand Junction Daily Sentinel

Jun 15, 2026

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$16.50
price up icon 1.01%
RDY RDY
$14.96
price down icon 3.12%
$24.61
price up icon 0.04%
$539.92
price up icon 0.40%
$54.10
price up icon 2.10%
大文字化:     |  ボリューム (24 時間):